Incorporando los inhibidores de CDK 4/6 a la práctica Clínica habitual

First line AI sensitive trials with CDK4/6 inhibitors

PALOMA 2 (2:1)

MONALEESA 2 (1:1)

Median PFS

abemaciclib + NSAI

not reached

placebo + NSAI

14.7 m

HR (95% CI): 0.543 (0.409, 0.723)

p=0.000021

MONARCH 3 (2:1)

Median PFS

Ribociclib + NSAI

25.3 m

placebo + NSAI

16 m

HR (95% CI): 0.568 (0.457, 0.704)

p=0.000000096

Median PFS

Palbociclib + NSAI

24.8 m

placebo + NSAI

14.5 m

HR (95% CI): 0.58 (0.46, 0.72)

p=<0.000001